Biogen Inc. vs Johnson & Johnson
BIIB vs JNJ — side-by-side comparison from reported financials. BIIB leads 2, JNJ leads 8 of 10 comparable metrics.
Biogen Inc.
BIIB · Healthcare
$225.71+3.33%Strained
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | BIIB | JNJ |
|---|---|---|
| Price | $225.71 | $261.79 |
| Market cap | $33.4B | $631B |
| Revenue (TTM) | $10.0B | $97.9B |
| Revenue growth | -0.9% | +5.6% |
| Net margin | 8.3% | 21.5% |
| Free cash flow | $2.70B | $22.2B |
| Net cash (debt) | $807M | ($27.8B) |
| 1-year price return | +50.9% | +37.0% |
| P/E | 40.0 | 29.9 |
| P/E vs own history (cheap-side %) | 1% | 16% |
| Dividend yield | — | 2.00% |
| Return on equity | 5% | 26% |
| CV checks passed | 8 of 10 | 10 of 10 |
| Employees | 7,500 | 140,800 |
Full résumé-style profiles: BIIB CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.